Maynard Um
-
-
-
-
-
-
-
BofA Securities Reiterates Underperform Rating on Lyell Immunopharma (LYEL), PT $12, 'we continue to view the story cautiously'
-
-
-
-
-
-
-
Lyell presents lymphoma trial data showing 93% response rate
-
-
-
-
-
-
-
Lyell Immunopharma (LYEL) PT Raised to $10 at H.C. Wainwright
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Neutral Rating on Lyell Immunopharma (LYEL)
-
-
404,876 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

